Blar i Bergen Open Research Archive på forfatter "Aas, Turid"
-
Age-Related Clusters and Favorable Immune Phenotypes in Breast Cancer of the Young Patients
Ingebriktsen, Lise Martine; Svanøe, Amalie Abrahamsen; Sæle, Anna Kristine Myrmel; Humlevik, Rasmus Olai Collett; Toska, Karen; Kalvenes, May Britt; Aas, Turid; Heie, Anette; Askeland, Cecilie; Knutsvik, Gøril; Stefansson, Ingunn Marie; Akslen, Lars Andreas; Høivik, Erling André; Wik, Elisabeth (Journal article; Peer reviewed, 2024)Breast cancer (BC) patients aged <40 years at diagnosis experience aggressive disease and poorer survival compared with women diagnosed with BC at 40 to 49 years, but the age-related biology is described to little extent. ... -
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Venizelos, Andreas; Engebrethsen, Christina; Deng, Wei; Geisler, Jürgen; Geisler, Stephanie; Iversen, Gjertrud Titlestad; Aas, Turid; Aase, Hildegunn Siv; Seyedzadeh, Manouchehr; Steinskog, Eli Sihn Samdal; Myklebost, Ola; Nakken, Sigve; Vodák, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Lønning, Per Eystein; Knappskog, Stian; Eikesdal, Hans Petter (Journal article; Peer reviewed, 2022)Background Subclonal evolution during primary breast cancer treatment is largely unexplored. We aimed to assess the dynamic changes in subclonal composition of treatment-naïve breast cancers during neoadjuvant ... -
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein (Peer reviewed; Journal article, 2015-10)Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on single gene mutations, we hypothesize chemoresistance to be due to inactivation of key pathways affecting cellular mechanisms such as ... -
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
Dejeux, Emelyne; Rønneberg, Jo A.; Solvang, Hiroko Kato; Bukholm, Ida Rashida Khan; Geisler, Stephanie; Aas, Turid; Gut, Ivo G.; Børresen-Dale, Anne-Lise; Lønning, Per Eystein; Kristensen, Vessela N.; Tost, Jörg (Peer reviewed; Journal article, 2010-03-25)Background: Breast cancer is the most frequent cancer in women and consists of a heterogeneous collection of diseases with distinct histopathological, genetic and epigenetic characteristics. In this study, we aimed to ... -
EMG changes during continuous intraoperative neuromonitoring with sustained recurrent laryngeal nerve traction in a porcine model
Brauckhoff, Katrin; Aas, Turid; Biermann, Martin; Husby, Paul (Peer reviewed; Journal article, 2016)Purpose: Traction is the most common cause of injury to the recurrent laryngeal nerve (RLN) in endocrine neck surgery. The purpose of this study was to evaluate specific alterations to the electromyogram (EMG) and verify ... -
Impact of EMG Changes in Continuous Vagal Nerve Monitoring in High-Risk Endocrine Neck Surgery
Brauckhoff, Katrin; Vik, Renate Kollevåg; Sandvik, Lorentz; Heimdal, John-Helge; Aas, Turid; Biermann, Martin; Brauckhoff, Michael (Peer reviewed; Journal article, 2016-03)Background: Continuous vagal intraoperative neuromonitoring (CIONM) of the recurrent laryngeal nerve (RLN) may reduce the risk of RLN lesions during high-risk endocrine neck surgery such as operation for large goiter ... -
Latencies longer than 3.5 ms after vagus nerve stimulation does not exclude a nonrecurrent inferior laryngeal nerve
Brauckhoff, Michael; Naterstad, Helle; Brauckhoff, Katrin; Biermann, Martin; Aas, Turid (Peer reviewed; Journal article, 2014-08-28)Background: It has recently been reported that a signal latency shorter than 3.5 ms after electrical stimulation of the vagus nerve signify a nonrecurrent course of the inferior laryngeal nerve. We present a patient with ... -
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Journal article; Peer reviewed, 2020)Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ... -
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjösne, Hans E.; Nysted, Arne; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, 2011-04-27)Background: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may ... -
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups
Askeland, Cecilie; Wik, Elisabeth; Finne, Kenneth; Birkeland, Even; Arnes, Jarle; Collett, Karin; Knutsvik, Gøril; Krüger, Kristi; Davidsen, Benedicte; Aas, Turid; Eide, Geir Egil; Stefansson, Ingunn; Foulkes, William; Akslen, Lars A. (Journal article; Peer reviewed, 2020)Studies indicate that stathmin expression associates with PI3K activation in breast cancer, suggesting stathmin as a marker for targetable patient subgroups. Here we assessed stathmin in relation to tumour proliferation, ... -
TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy
Eikesdal, Hans Petter; Knappskog, Stian; Aas, Turid; Lønning, Per Eystein (Peer reviewed; Journal article, 2014-10)Background: Before the advent of neoadjuvant chemotherapy, radiotherapy and surgery alone were associated with a high risk of uncontrolled locoregional relapses in locally advanced breast cancer (LABC). Material and methods: ...